Intercept Pharmaceuticals Stock News

Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.

Intercept Pharmaceuticals Inc  (NASDAQ: ICPT) stock is down 19.3% at $10.95, after a Food and Drug Administration (FDA) panel voted against recommending accelerated approval for its obeticholic acid

The FDA will likely reject Intercept Pharmaceuticals' highly watched liver disease treatment, analysts said Monday as ICPT stock crashed. The post Intercept Crashes As FDA Advisors Deliver The Likely

Shares of Intercept Pharmaceuticals Inc fell 16% on Monday over concerns about the prospects of the company's drug to treat a type of fatty liver disease after the regulator's advisory panel voted to

Shares of Intercept Pharmaceuticals Inc. ICPT, -1.95% tumbled 15.2% toward an 11-month low in premarket trading Monday, after the biopharmaceutical company said a U.S. Food and Drug Administration com

A panel of advisers to the U.S. Food and Drug Administration on Friday recommended holding off on an accelerated approval of Intercept Pharmaceuticals Inc's oral drug for a type of fatty liver disease

Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.

Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.

Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA s

Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.

Intercept Pharmaceuticals reported 2023 Q1 earnings today. The company missed Wall Street's revenue estimate for the three-month period by approximately $4.7 million.

Intercept Pharmaceuticals, Inc. (ICPT) Q1 2023 Earnings Call Transcript.

Intercept Pharmaceuticals (ICPT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.58 per share a year ago.

Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength

NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po